3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
3
Pain
2
Neoplasm Metastasis
2
Stomach Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Osteosarcoma
1
Neuroblastoma
1
Nerve Sheath Neoplasms
1
Neoplasms, Plasma Cell
1
Myoepithelioma
1
Multiple Myeloma
1
Kidney Neoplasms
1
Humoral Hypercalcemia Of Malignancy
1
Giant Cell Tumors of Bone
1
Desmoplastic Small Round Cell Tumor
1
Chordoma
1
Carcinoma, Renal Cell
1
Ascites
1
Adenocarcinoma
1
Interventions
pembrolizumab
26
Paclitaxel
22
Oxaliplatin
20
Nivolumab
16
Docetaxel
16
Capecitabine
16
Cisplatin
15
Fluorouracil
11
Cyclophosphamide
11
fludarabine
10
S 1 (combination)
10
Trastuzumab
9
Irinotecan
9
Carboplatin
8
Leucovorin
7
tislelizumab
6
aldesleukin
5
Ramucirumab
5
Interleukin-2
5
Gemcitabine
5
Drug Therapy
5
Bevacizumab
5
sintilimab
4
fludarabine phosphate
4
apatinib
4
Radiotherapy
4
Everolimus
4
regorafenib
3
olaparib
3
durvalumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Stomach Neoplasms
×
Zoledronic Acid
×
Clear all
NCT06759064
2025-11-19
IPIZA
Qilu Hospital of Shandong University
Phase 1/2
Recruiting
24 enrolled